Seres Therapeutics Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will take place November 29 December 2, 2021. The fireside chat will be available for on-demand viewing on the Seres website. About Seres Therapeutics Seres Ther

The stock price of Seres Therapeutics Inc (NASDAQ: MCRB) slightly increased pre-market today. This is why it happened.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres

The trading price of Seres Therapeutics Inc. (NASDAQ:MCRB) closed higher on Monday, November 22, closing at $9.17, 0.11% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Morgan Stanley raised its holdings in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 77.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 627,851 shares of the biotechnology companys stock after acquiring an additional 274,093 shares during the quarter. Morgan Stanley owned approximately 0.68% []

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have earned a consensus recommendation of Buy from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The []

Price T Rowe Associates Inc. MD trimmed its position in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 2.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,387,839 shares of the biotechnology companys stock after selling 29,503 shares during the period. Price T Rowe Associates []

Related Stocks: ISEE , ACRS , VRDN , KURA , PTGX , VTGN , DRNA , MRUS , TNYA , IOVA , RVMD , CNST , MGNX , EPIX , MRSN , MCRB ,

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2021 Results - Earnings Call Transcript

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 253.19% and 1681.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the sto

Red Light For Seres Therapeutics, But Not A Stop Light For Me

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcas

BiomX: Undervalued With Multiple Upcoming Catalysts

Seres Therapeutics Molecular Data On SER-109 Looks Good

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced late-breaking data from its Phase 3 ECOSPOR III study evaluating